ConductScience.org, home

Paper26918878

Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.

Quaglia A and 17 others. Histopathology, 2016. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation. Papers, record 26918878. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26918878

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.
PubMed
Journal
Histopathology
PubMed
Year
2016
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
0.82
iCite
Revised in PubMed
2017-11-01
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Quaglia AAlberto
2Alves VAVenancio A
3Balabaud CCharles
4Bhathal PSPrithi S
5Bioulac-Sage PPaulette
6Crawford JMJames M
7Dhillon APAmar P
8Ferrell LLinda
9Guido MMaria
10Hytiroglou PProdromos
11Nakanuma YYasuni
12Paradis VValerie
13Snover DCDale C
14Theise NDNeil D
15Thung SNSwan N
16Tsui WMWilson M S
17van Leeuwen DJDirk J
18International Liver Pathology Study GroupGroup

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Liver DiseasesMajor topic
Acute Disease
Biopsy
Carcinoma, Hepatocellular
Chronic Disease
Disease Progression
Humans
Liver
Liver Cirrhosis
Liver Neoplasms
Liver Regeneration
Male
Middle Aged
Parenchymal Tissue

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
41594255Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response.Diagnostics (Basel)2026https://conductscience.org/library/papers/41594255PubMed
40875093Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis.Aliment Pharmacol Ther2026https://conductscience.org/library/papers/40875093PubMed
38482630Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B.Saudi J Gastroenterol2024https://conductscience.org/library/papers/38482630PubMed
37511628Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications.Int J Mol Sci2023https://conductscience.org/library/papers/37511628PubMed
36195966ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis.Stem Cell Res Ther2022https://conductscience.org/library/papers/36195966PubMed
35043290Diagnostic performance of liver fibrosis assessment by quantification of liver surface nodularity on computed tomography and magnetic resonance imaging: systematic review and meta-analysis.Eur Radiol2022https://conductscience.org/library/papers/35043290PubMed
34909303A Comparative Analysis of the APRI, FIB4, and FibroScan Score in Evaluating the Severity of Chronic Liver Disease in Chronic Hepatitis B Patients in India.Cureus2021https://conductscience.org/library/papers/34909303PubMed
31391527Utility of glutamine synthetase immunohistochemistry in identifying features of regressed cirrhosis.Mod Pathol2020https://conductscience.org/library/papers/31391527PubMed
29700417Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification.Mod Pathol2018https://conductscience.org/library/papers/29700417PubMed
29589101Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al.Virchows Arch2018https://conductscience.org/library/papers/29589101PubMed
28834875Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohort study.Medicine (Baltimore)2017https://conductscience.org/library/papers/28834875PubMed
28725770Strategies for a Successful Anatomic Pathology Subspecialty Workgroup: The 26-Year Collaboration of "The Elves".Acad Pathol2016https://conductscience.org/library/papers/28725770PubMed
28710435Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection.Sci Rep2017https://conductscience.org/library/papers/28710435PubMed
28415736The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.Oncotarget2017https://conductscience.org/library/papers/28415736PubMed
28328813Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study.Medicine (Baltimore)2017https://conductscience.org/library/papers/28328813PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26918878

GET https://conductscience.org/api/papers/v1/26918878/authors